Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.…
Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics (NYSEAMERICAN: SER) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.
The shares were at 1.120 USD on 20 November 2026, down 71.9% over 52 weeks. Its 52-week range is 1.060 USD to 4.310 USD: the price is 74.0% below the high and 5.7% above the low.
Its market capitalisation is 29.76M USD.
Serina Therapeutics reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 19.27M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.